The European Medicines Agency released results of an internal survey that asked staff to which proposed cities they would consider relocating. The lowest-ranking city was one to which only 6% of respondents were likely or very likely to relocate.
This week, the European Medicines Agency (EMA) issued an update on its business continuity plan in preparation for the agency’s relocation. The EMA must move from its current location in London as the United Kingdom finalizes its withdrawal from the European Union.
As the focal point of its update, the EMA made public the results of a survey completed by 92% of EMA staff, which indicated that, for 65% of respondents, the eventual location of the EMA will be a determining factor in their decision to remain with the agency. In the worst-case scenario, the plan said, the agency could be left unable to function, and “As there is no backup, this would have important consequences for public health in the [European Union, EU].”
In the survey results, the EMA did not specify which cities had garnered higher or lower prospective retention rates, but disclosed that the top-ranking location was one to which 81% of respondents were likely or very likely to relocate. The lowest-ranking city was one to which only 6% of respondents were likely or very likely to relocate.
Using the survey results, the EMA broke the candidate locations into 4 groups:
The 19 cities with pending offers to host the EMA are as follows, in alphabetical order: Amsterdam, Netherlands; Athens, Greece; Barcelona, Spain; Bonn, Germany; Bratislava, Slovakia; Brussels, Belgium; Bucharest, Romania; Copenhagen, Denmark; Dublin, Ireland; Helsinki, Finland; Lille, France; Malta; Milan, Italy; Porto, Portugal; Sofia, Bulgaria; Stockholm, Sweden; Vienna, Austria; Warsaw, Poland; and Zagreb, Croatia.
European ministers will determine a new location for the EMA by vote in November, 2017. Under the complex voting system, each EU member state will be allowed to give 3 votes for its first choice, 2 for its second choice, and 1 for its third choice. If a city earns at least 14 separate 3-point votes, it will be named the winner. Otherwise, a second round of voting will proceed with a run-off among the 3 highest-scoring cities, with each member nation having 1 vote. In the event that no winner is determined in this second round, a final run-off will be held between the top 2 cities.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).